Biomy, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Teppei Konishi; hereinafter referred to as "our company"), which boasts advanced technology in the AI analysis of pathological images and spatial transcriptomics, has concluded a capital alliance agreement with Shin Nippon Biomedical Laboratories, Ltd. (Headquarters: Kagoshima City, Kagoshima Prefecture; Representative Chairman, President and CEO: Ryoichi Nagata; hereinafter referred to as "SNBL"). The total amount raised to date is approximately 92 million yen.
SNBL, the underwriter of this agreement, is Japan's first nonclinical contract research organization (CRO) founded in 1957. As the only company in Japan capable of handling all stages of pharmaceutical development, including basic research and drug discovery, SNBL is committed to supporting partner companies in new drug development. This partnership is expected to generate significant business synergies, not only by deploying our technologies but also in new business development.
Our company aims to realize personalized medicine through pathological AI technology. Our pathological AI software, "DeepPathFinder," is utilized by pharmaceutical companies and research institutions.
In recent years, with the advancement of cancer immunotherapy and molecular targeted therapy, the importance of the "tumor microenvironment (TME)," which constitutes the area surrounding the tumor, has become clear in terms of drug efficacy and patient prognosis. We particularly focus on the spatial information of various immune cells that make up the TME for each patient. The TME consists of tens of thousands to hundreds of thousands of cells, making it challenging to identify and quantify this spatial information in routine clinical practice. Our company possesses unique pathological AI technology to identify and quantify these cells and conducts research to establish new efficacy indicators and patient stratification. Recently, we have also developed analysis technology combining pathological images with spatial transcriptomics. Additionally, we are developing analysis algorithms through joint research with Professor Shumpei Ishikawa of the Department of Hygiene, Graduate School of Medicine, The University of Tokyo, a leading expert in pathological image AI.
With the funds raised this time, we will promote the development of pathological AI software and strengthen our sales structure both domestically and internationally.
Furthermore, our research theme, "Development of an Integrated Analysis Platform for Pathological Images and Spatial Transcriptome Data Using Generative AI," has been selected for the "Ministry of Economy, Trade and Industry's FY2024 Growth-Oriented Small and Medium Enterprise R&D Support Project (Go-Tech Project)." We will promote research and development in collaboration with The University of Tokyo and the Bio-Industrial Information Consortium. The total subsidy amount is approximately 95 million yen.
Ministry of Economy, Trade and Industry, Kanto Bureau of Economy, Trade and Industry (Announcement on June 24, 2024): The FY2024 Growth-Oriented Small and Medium Enterprise R&D Support Project (Go-Tech Project) has been selected: https://www.kanto.meti.go.jp/seisaku/sapoin/r6fy_go-tech_saitaku1.html
Our company will continue to advance research and development aiming for the realization of personalized medicine through AI.